Testare un intervento decisionale mammografico in un ambiente rurale
Verso l'ottimizzazione di una sperimentazione di aiuto decisionale mammografico e di intervento di comunicazione medica per ambienti rurali
The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a three-arm randomized pilot trial that will enroll 30 participants over two study phases. The main objective is to achieve data on trial feasibility (recruitment, retention, randomization, adherence, and acceptability). The primary outcome is Intervention Acceptability.
Procedures: PCPs will be randomized to one of the three arms to prevent contamination across patients (usual care, decision aid, decision aid + clinician communication). Patients will be considered for enrollment if they are aged 40-49, English or Spanish-speaking, have an upcoming primary care visit within 4 weeks, no history of breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or atypical hyperplasia, and no mammogram within the past 12 months. These patients will be identified via the electronic health record using routine data reports provided to the study team.
Data Collection: Surveys will be conducted at baseline (pre-intervention), post-DA and Post-Visit. Mammography screening information will be collected via medical records, and implementation data will be completed with patients and clinicians who were exposed to the decision aid intervention.
Analysis: All feasibility metrics will be summarized quantitatively, distributions examined for central tendency and spread, and all data assessed for completeness. Data will be presented in a tabular format, with means and standard deviations summarized for the Acceptability of Intervention Measure. Process data will likewise be summarized, reporting proportions of participants meeting each metric (recruitment, retention, randomization, adherence).
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Christine M Gunn, PhD
- Numero di telefono: 603-646-5430
- Email: Christine.M.Gunn@dartmouth.edu
Luoghi di studio
-
-
New Hampshire
-
Keene, New Hampshire, Stati Uniti, 03431
- Reclutamento
- Cheshire Medical Center
-
Contatto:
- Christine Gunn, PhD
- Numero di telefono: 603-646-5430
- Email: Christine.M.Gunn@dartmouth.edu
-
New London, New Hampshire, Stati Uniti, 03257
- Reclutamento
- New London Hospital Primary Care
-
Contatto:
- Christine Gunn
- Numero di telefono: (603) 646-5430
- Email: christine.m.gunn@dartmouth.edu
-
Newport, New Hampshire, Stati Uniti, 03773
- Reclutamento
- Newport Health Center
-
Contatto:
- Christine Gunn
- Email: christine.m.gunn@dartmouth.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Patient Inclusion Criteria:
- Females
- Aged 39-49
- Upcoming appointment with a participating primary care provider (within 4 weeks)
- English or Spanish-speaking
Patient Exclusion Criteria:
- Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia)
- Mammogram in the prior 9 months
Clinician inclusion: Any practicing primary care provider at a participating site.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Nessun intervento: Usual Care
Usual care. |
|
|
Sperimentale: MyMammogram
Patient uses MyMammogram prior to appointment. |
An online breast cancer screening decision aid |
|
Sperimentale: MyMammogram plus provider communication
Patient uses MyMammogram prior to appointment. Provider receives a summary from MyMammogram prior to appointment. |
An online breast cancer screening decision aid Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Intervention acceptability
Lasso di tempo: within one day of completing the intervention
|
The acceptability e-scale is a 6-item measure for electronically-delivered interventions, where higher scores indicate greater acceptability. Scores range from 6-30. |
within one day of completing the intervention
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recruitment feasibility
Lasso di tempo: 4 weeks
|
Measured as the proportion of eligible participants who receive an initial outreach letter and complete the consent process and enroll prior to their clinical visit. |
4 weeks
|
|
Retention feasibility
Lasso di tempo: 8 weeks
|
Proportion of participants enrolled who complete all study survey time points, reported per trial arm |
8 weeks
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Knowledge
Lasso di tempo: enrollment and within one day of completing the intervention
|
10-item measure of breast cancer and screening knowledge that is summed for a score from 0-10 (0 indicates lower knowledge, 10 indicates higher knowledge). |
enrollment and within one day of completing the intervention
|
|
Decisional Quality
Lasso di tempo: enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
Decisional Quality is measured using the Decisional Conflict Scale for Low Literacy, a 10-item measure. Scores Range 0-100. Lower scores indicate better decisional quality (lower conflict). |
enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
|
Screening Intentions
Lasso di tempo: enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
Screening intentions are using two methods. 1) As the likelihood of obtaining a mammogram in the next year (5-point Likert scale); and 2) Using 2 items to measure age at which someone intends to begin screening (40, 45, 50, other) and interval (annual, biennial, other). |
enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
|
Shared Decision-Making
Lasso di tempo: within one day of completing a clinical visit
|
Shared Decision Making will be assessed with the 3-item, validated CollaboRATE measure. Scored 0-100 (higher scores indicate more shared decision-making). |
within one day of completing a clinical visit
|
|
Self-efficacy
Lasso di tempo: enrollment and within one day of completing a clinical visit
|
Measured using a validated scale measuring perceived confidence one's personal ability to obtain a mammogram. Ten items are summed, with a theoretical score range from 5-10 (higher scores indicate better self-efficacy). |
enrollment and within one day of completing a clinical visit
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- STUDY02002381
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .